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A B S T R A C T
Purpose
Enzalutamide resistance could result from raised androgens and be overcome by combination with
abiraterone acetate. PLATO (ClinicalTrials.gov identiﬁer: NCT01995513) interrogated this hypothesis
using a randomized, double-blind, placebo-controlled design.
Patients and Methods
In period one, men with chemotherapy-naı¨ve metastatic castration-resistant prostate cancer re-
ceived open-label enzalutamide 160 mg daily. Men with no prostate-speciﬁc antigen (PSA) increase
at weeks 13 and 21 were treated until PSA progression ($ 25% increase and $ 2 ng/mL above
nadir), then randomly assigned at a one-to-one ratio in period two to abiraterone acetate 1,000 mg
daily and prednisone 5 mg twice daily with either enzalutamide or placebo (combination or control
group, respectively) until disease progression as deﬁned by the primary end point: progression-free
survival (radiographic or unequivocal clinical progression or death during study). Secondary end
points included time to PSA progression and PSA response in period two.
Results
Of 509 patients enrolled in period one, 251 were randomly assigned in period two. Median
progression-free survival was 5.7 months in the combination group and 5.6 months in the control
group (hazard ratio, 0.83; 95% CI, 0.61 to 1.12; P = .22). There was no difference in the secondary
end points. Grade 3 hypertension (10% v 2%) and increased ALT (6% v 2%) or AST (2% v 0%) were
more frequent in the combination than the control group.
Conclusion
Combining enzalutamide with abiraterone acetate and prednisone is not indicated after PSA pro-
gression during treatment with enzalutamide alone; hypertension and elevated liver enzymes are
more frequent with combination therapy.
J Clin Oncol 36:2639-2646. © 2018 by American Society of Clinical Oncology. Creative Commons
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INTRODUCTION
Enzalutamide, a potent androgen receptor (AR)
antagonist, and abiraterone acetate (administered
in combination with prednisone and hereafter
referred to as abiraterone), a potent inhibitor of
cytochrome P450 (CYP17A1) that suppresses
androgen synthesis, induce declines in prostate-
speciﬁc antigen (PSA) in up to 90% of patients
when administered alone to men with metastatic
castration-resistant prostate cancer (mCRPC).1,2
Both improve survival and are approved for the
ﬁrst-line treatment of chemotherapy-na¨ıvemCRPC.
However, resistance develops after a median of
approximately 18 months, and strategies that pro-
long treatment beneﬁt are urgently required. A
rise in PSA, suggesting reactivation of AR target
genes, is often associated with clinical progres-
sion.3 Several mechanisms have been implicated
in driving resistance and can be broadly divided
into categories that are either dependent on or
independent of ligand-binding domain-driven
reactivation of AR signaling.3 The former can
include an adaptive feedback loop of increased
serum and tissue androgens and AR levels after
AR antagonism with enzalutamide4 that in vitro
modeling suggests could result in outcompeting
of enzalutamide at the AR.5 A single-center,
single-arm study of the combination of abiraterone
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and enzalutamide reported manageable toxicity and no mean-
ingful pharmacokinetic drug-drug interactions.6
PLATO was designed to investigate enzalutamide resistance,
which is thought to be attributable to ligand-binding domain
reactivation of AR signaling. We hypothesized that cross-resistance
may exist between single-agent enzalutamide and abiraterone,
making their use in sequence of limited beneﬁt, and that a rise in
androgens in patients receiving enzalutamide may result in
reactivation of AR, so that disrupting this adaptive feedback loop
by combining with abiraterone would reinduce enzalutamide
sensitivity, resulting in prolonged patient beneﬁt and tumor
responses versus abiraterone alone. Abiraterone effectively in-
hibits androgen synthesis,7 but we hypothesized that raised levels
of progesterone, synthetic glucocorticoids, and other potential
ligands with abiraterone in the presence of high AR levels after
enzalutamide treatment would result in continued AR activity
and primary resistance (Fig 1A).8-10 To test these hypotheses, we
used a novel trial design whereby patients received open-label
enzalutamide and at predeﬁned PSA progression were randomly
assigned to receive abiraterone plus placebo or abiraterone plus
enzalutamide (Fig 1B). Combining abiraterone with enzaluta-
mide would not inhibit reactivation of AR independent of the
ligand-binding domain, including resistance mediated by AR
splice variants or glucocorticoid receptors.11,12 To attempt en-
richment for cancers more likely to beneﬁt from the combination
of enzalutamide and abiraterone, we excluded patients who had




This trial comprised consecutive periods of open-label treatment
with enzalutamide 160 mg orally once daily (period one) followed by
randomized, double-blind treatment in period two (Fig 1B). Men with
no PSA increase from baseline at weeks 13 and 21 in period one con-
tinued treatment until PSA progression (deﬁned as a $ 25% increase
and $ 2 ng/mL above nadir that required conﬁrmation by a second
consecutive PSA assessment $ 3 weeks later). They were then randomly
































Primary and secondary end points of the trial
Enrolled, n = 509
(target, n = 500)
PSA nonprogressors, n = 408
(target, n = 415)
Randomly assigned, n = 251
(target, n = 250)
PFS events, n = 175
(target, n = 175)



































Fig 1. (A) Scientiﬁc hypotheses underlying PLATO trial and (B) PLATO trial design. Actual patient numbers at each trial milestone are included on the bottom row of
panel B, and target numbers are included in brackets. More details on period one patient disposition are provided in the Data Supplement. AR, androgen receptor;
PFS, progression-free survival; PSA, prostate-speciﬁc antigen. (*) Random assignment was stratiﬁed by conﬁrmed PSA response at week 13 in period one ($ 0% to, 30% v
$ 30%).
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160 mg daily or blinded enzalutamide placebo (capsules identical in
appearance to enzalutamide) orally once daily in combination
with open-label abiraterone 1,000 mg orally once daily and open-
label prednisone 5 mg orally twice daily. Randomization was
stratiﬁed by PSA$ 30% decline at period one week 13 ($ 0 to, 30%
v $ 30%).
Patients not eligible for period two were allowed to continue open-
label enzalutamide in period one until loss of clinical beneﬁt as assessed
by the investigator and thereafter underwent safety follow-up. In period
two, discontinuation because of PSA progression was discouraged, and
administration of study drugs continued until disease progression as
deﬁned by the primary end point, intolerable toxicity, or patient
withdrawal, whichever occurred ﬁrst. Patients who chose to discontinue
before meeting the primary end point were censored. PLATO was ap-
proved by the independent board at each participating site and conducted
according to the provisions of the Declaration of Helsinki and Good
Clinical Practice Guidelines of the International Conference on Har-
monisation. All patients provided written informed consent before
participating.
Patients
Eligible patients starting period one had histologically conﬁrmed,
asymptomatic or minimally symptomatic prostate cancer (deﬁned as
a score of , 4 on Brief Pain Inventory–Short Form [BPI-SF] question
three), Eastern Cooperative Oncology Group performance status of # 1,
and chemotherapy-naı¨ve disease that progressed during androgen-
deprivation therapy as deﬁned by the Prostate Cancer Clinical Trials
Working Group 2.13 For periods one and two, patients were required to
have: conﬁrmation of metastases using whole-body radionuclide bone
scan and computed tomography or magnetic resonance imaging;
castrate levels of testosterone (# 1.73 nmol/L) and prior bilateral
orchiectomy or inhibition of gonadotropin-releasing hormone
throughout the study; no history of predisposition to seizures or known
brain metastases; no clinically signiﬁcant cardiovascular disease; and no
prior treatment of prostate cancer with cytotoxics, aminoglutethimide,
ketoconazole, abiraterone, or enzalutamide or an investigational agent
that inhibited the AR or androgen synthesis. Additionally, for period
two, patients were required to have conﬁrmed PSA progression and
were excluded if they had cancer-related pain requiring chronic opiate
use (excluding acetaminophen acetate ﬁxed-dose combinations), which
was deﬁned as daily use for . 7 consecutive days or . 10 days within
a 14-day period.
Assessments
During period one, PSAvalues weremonitored at screening, baseline,
weeks 13 and 21, and every 4 weeks thereafter. During period two, PSA
values were monitored at screening, weeks 9 and 13, and every 8 weeks
thereafter. Radiographic images were assessed at screening in periods one
and two, every 8 weeks in period two after random assignment for
32 weeks, and every 12 weeks thereafter or earlier than scheduled if
progression was clinically suspected. Radiographic disease progression
was deﬁned in soft tissue using Response Evaluation Criteria in Solid
Tumors (version 1.1) and in bone using Prostate Cancer Clinical Trials
Working Group 2 criteria as done previously.1 Radiologic assessments
were conducted by designated readers at individual sites. Pain was
assessed using the BPI-SF questionnaire, and quality of life was assessed
using the Functional Assessment of Cancer Therapy–Prostate (FACT-P)
questionnaire. Use of cytotoxic chemotherapy, cancer vaccines, or ex-
perimental therapies for the treatment of cancer was prohibited during
the study. Use of bisphosphonates or denosumab was allowed if initiated
$ 4 weeks before random assignment and the dose was stable. After
discontinuation of period two study drugs, patients had a safety follow-
up assessment at 4 weeks and were monitored at 4-week intervals for
16 weeks.
Outcomes
Primary and secondary end points were assessed using data ob-
tained in period two. The primary end point was progression-free
survival (PFS), deﬁned as the time from random assignment to the
ﬁrst of the following events assessed by the investigator: radiographic
progression, unequivocal clinical progression, or death during study
(ie, death from random assignment to within 112 days [ie, four cycles]
of treatment discontinuation without objective evidence of radio-
graphic progression). Unequivocal clinical progression was deﬁned as
any of the following: new onset of prostate cancer pain requiring
chronic opiate use as deﬁned previously, deterioration of Eastern
Cooperative Oncology Group performance status to $ 3 as a result of
prostate cancer, initiation of cytotoxic chemotherapy for prostate
cancer, or radiation therapy or surgical intervention because of com-
plications of tumor progression. Secondary end points were time to PSA
progression, PSA response of $ 50%, PSA response of $ 30%, rate of
pain progression, objective response rate, time to ﬁrst use of subsequent
antineoplastic therapy, time to degradation of FACT-P score, and safety
using the National Cancer Institute Common Terminology Criteria for
Adverse Events (version 4). Assessments of safety included adverse
events, clinical laboratory tests, physical examinations, vital signs, and
12-lead ECGs.
Statistical Analyses
Estimated median PFS was 5 and 8 months for the control and
combination groups, respectively. An estimated 175 events were re-
quired to achieve a target hazard ratio (HR) of approximately 0.63 with
a two-sided 5% type I error rate and approximately 85% power. Ap-
proximately 500 patients with mCRPC were to be enrolled, with 83%
expected to have no rise in PSA at weeks 13 and 21. Of these, ap-
proximately two thirds were expected to have PSA progression by
planned closure of random assignment, and approximately 10% were
expected to drop out of the study. Therefore, approximately 250 pa-
tients with PSA progression were expected to be randomly assigned to
double-blind treatment in period two, with approximately 70% of these
expected to demonstrate radiographic or unequivocal clinical pro-
gression or death during study to achieve the target number of 175
events. Estimates of median PFS were determined using the Kaplan-
Meier method. Prespeciﬁed sensitivity analyses using the same methods
were designed to assess the interaction of ﬁve predeﬁned factors on
the primary end point of PFS. If the primary end point was met, the
key secondary end points (time to PSA progression and PSA re-
sponse of $ 50%) would be tested using a gatekeeping procedure to
control for experiment-wise type I error.14 P values for other sec-
ondary efﬁcacy analyses were exploratory, and no adjustment for
multiplicity was to be performed. All efﬁcacy analyses were per-
formed in the intention-to-treat population, and differences in time
to event were calculated using the log-rank test stratiﬁed by period
one week 13 PSA decline ($ 0% to , 30% v $ 30%). HRs were
calculated based on a Cox regression model with treatment as the only
covariate and stratiﬁed by period one week 13 PSA decline ($ 0% to
, 30% v $ 30%), with , 1.00 favoring the combination group. All
safety analyses were performed in the population receiving any study
treatment.
RESULTS
Patient Characteristics and Disposition
A total of 509 patients enrolled in period one at 51 sites in
North America, Europe, and Australia and received open-label
single-agent enzalutamide. Baseline patient characteristics for
period one are listed in the Data Supplement; 370 (73%) of 509
patients had received a ﬁrst-generation antiandrogen, 151 (30%)
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were receiving a stable dose of bisphosphonates or denosumab,
and 421 (83%) had bone metastases on bone scan. Median
duration of treatment with single-agent enzalutamide in period
one was 9.1 months; 377 (74%) and 340 patients (67%) had a PSA
decline of $ 30% and $ 50%, respectively, at week 21 (Data
Supplement). Overall, 408 patients had stable or decreased PSA
levels at weeks 13 and 21 and were therefore eligible to enter
period two when they developed PSA progression (Data Sup-
plement). Of these, 251 patients had conﬁrmed PSA progression,
met period two eligibility criteria, and were randomly assigned to
one of the two treatment groups before the cutoff date of October
7, 2016. A total of 126 were assigned to enzalutamide plus
abiraterone and prednisone (combination group), and 125 were
assigned to placebo plus abiraterone and prednisone (control
group; Fig 1B). All except one patient in each treatment group
received study treatment (Fig 2). Patient characteristics at
screening for period two by treatment group are listed in Table 1.
At the data cutoff for the primary analysis, of the 258 patients
who were not randomly assigned, 84 (33%) continued enza-
lutamide and 174 (67%) discontinued period one, primarily
because of disease progression (Data Supplement). Of the 251
patients randomly assigned, 27 (21%) of 126 patients in the
combination group and 18 (14%) of 125 patients in the control
group continued treatment (Fig 2).
Primary End Point
Median treatment duration in period two was 5.6 months for
both groups. Median PFS was 5.7 and 5.6 months for the com-
bination and control groups, respectively (HR, 0.83; 95% CI, 0.61
to 1.12; P = .22; Fig 3). A predeﬁned analysis of the PFS event by
unequivocal clinical or radiographic progression or death sug-
gested a difference in the proportion of events by treatment group,
with a higher rate of clinical progression events in the combination
group and a higher rate of radiologic events in the control group
(Table 2).
Sensitivity Analyses
In a predeﬁned sensitivity analysis to determine the impact of
unequivocal clinical progression on the duration of PFS, which
included only events of radiographic progression or death during
study and censored patients with unequivocal clinical progression,
median PFS was 10.0 and 7.0 months for the combination and
control groups, respectively (HR, 0.67; 95% CI, 0.47 to 0.94;
P = .02; Data Supplement). The results of the other prespeciﬁed
sensitivity analyses, including those to determine the impact of
antineoplastic therapies, treatment discontinuation, unconﬁrmed
bone disease progression, and disease progression at unsched-
uled visit, were not statistically signiﬁcant (Data Supplement).
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Fig 2. Patient disposition in period two.
ECOG PS, Eastern Cooperative Oncology
Group performance status. (*) Reasons in-
cluded clinical disease progression and rising
prostate-speciﬁc antigen. (†) Reasons in-
cluded rising prostate-speciﬁc antigen and
disease metastasis.
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Predeﬁned subgroup analyses showed that the treatment effects
were broadly consistent across subgroups; differences were ob-
served for those receiving opiates or those with visceral disease, but
these groups were small (Data Supplement).
Secondary End Points
Because the primary end point was not met, all analyses of
secondary end points were exploratory. In period two, 124
(98%) of 126 patients in the combination group and 122 (98%)
of 125 patients in the control group had a baseline and at least
one postbaseline PSA assessment. One (1%) of 124 patients in
the combination group and three (2%) of 122 patients in the
control group had a conﬁrmed reduction in baseline PSA of
$ 50%; Fig 4A). Median time to PSA progression was
2.8 months for both groups (HR, 0.87; 95% CI, 0.62 to 1.24;
P = .45; Fig 4B). There was no difference between the two groups
with regard to rate of pain progression, objective response rate,
or time to ﬁrst use of subsequent antineoplastic therapy (Data
Supplement). FACT-P score degradation was observed in 67
(53%) of 126 patients in the combination group and 54 (43%) of
125 patients in the control group. There was no difference in
median time to degradation of FACT-P score (4.6 months; 95%
CI, 3.7 to 6.5 v 6.4 months; 95% CI, 5.5 to 13.9, respectively; HR,
1.40; 95% CI, 0.97 to 2.03; P = .07).
Safety
In period one, 35 (7%) of 509 patients had an adverse event
that led to discontinuation of enzalutamide. The most common
enzalutamide-related adverse events of any grade were fatigue
in 173 patients (34%) and hot ﬂushes in 74 (15%; Data Sup-
plement). In period two, 102 (41%) of 249 patients had at
least one grade $ 3 adverse event (56 [45%] of 125 in the
combination group; 46 [37%] of 124 in the control group). The
two most common grade $ 3 events were hypertension and
a rise in ALT in 12 (10%) and seven patients (6%) in the
combination group, respectively, and in two (2%) and three
patients (2%) in the control group (Table 3). Eleven patients
(9%) in the combination group and ﬁve patients (4%) in the
control group had an adverse event that was the primary
reason for discontinuation of enzalutamide or placebo. Twelve
patients (10%) receiving the combination and four patients
(3%) in the control group had an adverse event that was the
primary reason for discontinuation of abiraterone. Nineteen
patients (8%) had an adverse event leading to abiraterone
dose reduction (11 [9%] receiving the combination; eight [6%]
in the control group), and 60 patients (24%) had an adverse











0 79 (63) 84 (67)
1 47 (37) 41 (33)
BPI-SF question 3*
0-1 74 (59) 71 (57)
2-3 27 (21) 33 (26)














Bone 113 (90) 112 (90)
Lymph node 52 (41) 56 (45)
Visceral disease, lung or liver 8 (6) 5 (4)
Other soft tissue 13 (10) 15 (12)
No. of bone metastases
0 13 (10) 12 (10)
1-4 37 (29) 44 (35)
5-9 24 (19) 22 (18)
10-20 22 (17) 19 (15)
. 20 30 (24) 27 (22)
Missing information 0 1 (, 1)
Abbreviations: ALP, alkaline phosphatase; BPI-SF, Brief Pain Inventory–Short
Form; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR,
interquartile range; PSA, prostate-speciﬁc antigen.






































HR, 0.83; 95% CI, 0.61 to 1.12; P = .22
Fig 3. Kaplan-Meier estimates for pro-
gression-free survival (PFS). Dotted line
represents median. HR, hazard ratio.
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event leading to temporary interruption of abiraterone (37
[30%] receiving the combination; 23 [19%] in the control
group).
DISCUSSION
PLATO evaluated reinduction of sensitivity to AR antagonism by
combining enzalutamide with abiraterone to treat patients with
a rising PSA while receiving enzalutamide. The comparator arm
was common practice in several parts of the world, where abir-
aterone is often used after enzalutamide. Because the PLATO
design randomly assigned patients who had received single-agent
enzalutamide until conﬁrmed PSA progression, a primary end point
was used that included unequivocal clinical progression. This dif-
fered from the regulatory COU-AA-302 and PREVAIL trials, which
mandated radiographic progression,1,2 and was considered neces-
sary because of the ethical and pragmatic challenges of continuing
AR-targeting therapy in men with a rising PSA and worsening
symptoms, given the risk of patients becoming too unwell for the
next proven effective line of treatment with docetaxel. In fact, ap-
proximately one ﬁfth of patients at screening before random as-
signment in period two had a pain score of . 3 on question three
(worst pain in the previous 24 hours) of the BPI-SF.
PLATO did not meet its primary end point. Consequently, the
gatekeeping procedure was not used, and secondary analyses were
not adjusted for multiplicity and were considered exploratory. These
included a sensitivity analysis for radiographic PFS that showed
a nominally signiﬁcant difference beneﬁting the combination group.









Total events 83 (66) 92 (74)
Radiographic progression 47 (37) 69 (55)
Bone progression 20 (16) 36 (29)
Soft tissue progression 27 (21) 31 (25)
Concurrent bone and soft tissue progression 0 2 (2)
Unequivocal clinical progression 32 (25) 22 (18)
Chronic opiate use 14 (11) 6 (5)
Deterioration of ECOG PS to $ 3 4 (3) 1 (1)
Initiation of cytotoxic chemotherapy 8 (6) 12 (10)
Initiation of radiotherapy 3 (2) 1 (1)
Initiation of surgical intervention 2 (2) 2 (2)
Concurrent chronic opiate use and surgical
intervention
1 (1) 0
Concurrent soft tissue progression and chronic
opiate use
1 (1) 0
Death during study 3 (2) 1 (1)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance










































































HR, 0.87; 95% CI, 0.62 to 1.24
Fig 4. (A) Best single prostate-speciﬁc
antigen (PSA) change in period two and (B)
Kaplan-Meier estimate for time to PSA pro-
gression. Dotted lines represent (A) PSA
declines of 30%, 50%, and 90% and (B)
median. HR, hazard ratio.
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This may have been subject to multiple biases, including more clinical
progression events (25% v 18%) before conﬁrmation of radiographic
progression for the combination group versus the control group.
A small increase in the risk of hepatic impairment and un-
controlled hypertension was reported in the combination group.
Although in general the toxicity was manageable, more patients in
the combination group than in the control group discontinued
treatment because of adverse events, which also may have con-
tributed to symptomatic worsening and earlier treatment dis-
continuation. Pharmacokinetic data were not evaluated for drug-
drug interactions; however, the rates of hypokalemia and liver
function abnormalities were similar to those in previous studies of
single-agent abiraterone,15,16 suggesting that exposure to active
abiraterone metabolites was not compromised.
PLATO also reported limited beneﬁt with abiraterone after
enzalutamide. This was not a primary aim of the trial but is
concordant with several retrospective studies17-19 published after
PLATO was designed that support our hypothesis of low response
rates for abiraterone after enzalutamide. Other trials have reported
limited beneﬁt with enzalutamide after abiraterone.20 Several clinical
trials have been initiated to evaluate the combination of CYP17A1
inhibition and AR antagonism, both in patients with mCRPC
(ClinicalTrials.gov identiﬁers: NCT01650194 and NCT01949337)
and in hormone-na¨ıvemen starting long-term androgen-deprivation
therapy (ClinicalTrials.gov identiﬁer: NCT02268175),21 with the ﬁrst
of these expected to be reported in 2018.
Overall, results from PLATO suggest that enzalutamide should
not be continued in combination with abiraterone after PSA
progression during enzalutamide monotherapy. Because of the
exclusion of patients who had a PSA rise at 13 or 21 weeks while
receiving single-agent enzalutamide (8% of patients; Data Sup-
plement), the lack of representation of long-term single-agent
enzalutamide responders (17% continued single-agent enzaluta-
mide at study closure; Data Supplement), and the absence of
a molecular biomarker for enriching for sensitive patients, PLATO
may have missed a signal of beneﬁt in these subgroups. Ongoing
exploratory biomarker analyses from PLATO using plasma DNA
data as described previously10,22 aim to identify molecularly se-
lected patients who may beneﬁt from the combination of enza-
lutamide with abiraterone.
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Table 3. TEAEs by Decreasing Frequency
Event
No. (%)
Combination Group (n = 125) Control Group (n = 124)
Any Grade Grade $ 3 Any Grade Grade $ 3
No. of patients with reports of $ 1 TEAE 112 (90) 56 (45) 113 (91) 46 (37)
Back pain 26 (21) 3 (2) 28 (23) 1 (1)
Fatigue 17 (14) 0 18 (15) 1 (1)
Hypertension 25 (20) 12 (10) 9 (7) 2 (2)
Arthralgia 18 (14) 1 (1) 14 (11) 1 (1)
Nausea 21 (17) 0 11 (9) 0
Constipation 17 (14) 1 (1) 12 (10) 0
Decreased appetite 13 (10) 1 (1) 10 (8) 0
Peripheral edema 7 (6) 0 16 (13) 1 (1)
Musculoskeletal chest pain 13 (10) 0 7 (6) 1 (1)
Increased ALT 10 (8) 7 (6) 6 (5) 3 (2)
Hypokalemia 9 (7) 2 (2) 7 (6) 3 (2)
Increased AST 5 (4) 3 (2) 2 (2) 0
Spinal cord compression 4 (3) 3 (2) 2 (2) 2 (2)
Metastatic pain 3 (2) 3 (2) 2 (2) 2 (2)
NOTE. Treatment-emergent adverse events (TEAEs) of any grade reported in $ 10% of patients or of grade $ 3 reported in $ one patient in either treatment group.
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